EAGLE PHARMACEUTICALS, INC.

Form 4

Common

Stock

11/30/2016

11/30/2016

December 02, 2016

FORM 4 UNITED STATES SECURITIES AND EVOLUNCE COMMISSION							OMB APPROVAL				
Washington, D.C. 20549								OMB Number:	3235-0287		
Check this box								Expires:	January 31,		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITES Estimated average burden hours per response 10.5 Estimated average burden hours per response 10.5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type Responses)											
Krill Steven L. Symb			2. Issuer Name and Ticker or Trading ymbol AGLE PHARMACEUTICALS,				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		INC. [E	INC. [EGRX]				(Check an applicable)				
(Last) C/O EAGLE PHARMAC TICE BLVE	(Month/E 11/23/2	Date of Earliest Transaction Ionth/Day/Year) /23/2016				Director 10% Owner Other (specify below) EVP & Chief Scientific Officer					
	(Street)	4. If Ame	ndment, Da	te Original			6. Individual or Jo	oint/Group Filir	ng(Check		
	nth/Day/Year)				Applicable Line)						
WOODCLIFF LAKE, NJ 07677 Form filed by One Reporting Person Form filed by More than One Reporting Person											
(City)	(State) (Zip) Tabl	e I - Non-D	erivative S	Securi	ities Acc	quired, Disposed of	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A)			Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)				
Common Stock	11/23/2016		M	200	A	\$ 8.78	200	D			
Common Stock	11/23/2016		S	200	D	\$ 80	0	D			
Common Stock	11/30/2016		M	1,950	A	\$ 8.78	1,950	D			

1,950 D

2,530 A

\$ 80 0

2,530

S

M

D

D

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

Common Stock					\$ 8.78		
Common Stock	11/30/2016	S	2,530	D	\$ 80	0	D
Common Stock	11/30/2016	M	1,307	A	\$ 4.42	1,307	D
Common Stock	11/30/2016	S	1,307	D	\$ 80	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 8. I De Sec (In

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 8.78	11/23/2016		M		200	<u>(1)</u>	07/11/2022	Common Stock	200
Stock Option (right to buy)	\$ 8.78	11/30/2016		M		1,950	<u>(2)</u>	09/25/2021	Common Stock	1,950
Stock Option (right to buy)	\$ 8.78	11/30/2016		M		2,530	<u>(1)</u>	07/11/2022	Common Stock	2,530
Stock Option (right to buy)	\$ 4.42	11/30/2016		M		1,307	(3)	04/18/2023	Common Stock	1,307

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer

Other

Krill Steven L. C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE, NJ 07677

EVP & Chief Scientific Officer

Signatures

/s/ Scott Tarriff, Attorney-in-Fact

12/02/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the option vested on July 12, 2013 and the remainder vested in equal monthly installments over a period of three years.
- (2) 25% of the shares subject to the option vested on September 26, 2012 and the remainder vested in equal monthly installments over a period of three years.
- (3) 25% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3